There is growing evidence that GVHD affects the central nervous system (CNS). In this study, we describe the longterm follow-up of four allogeneic BM recipients who developed cerebral angiitis-like disease probably due to GVHD. The patients developed focal neurological signs, cognitive deficits and/or coma in association with GVHD, 2-18 years after transplantation, following reduction of immunosuppressive therapy. Magnetic resonance imaging was variable, showing generalized brain atrophy, ischemic lesions or leukoencephalopathy. Diagnosis of cerebral angiitis was confirmed by histopathological analysis of bioptic brain tissue and response to immunosuppressive therapy. By means of immunohistochemistry and immunofluorescence, perivascular lymphomononuclear cerebral infiltrates were shown to express the adhesion receptor, CD11a, and the chemokine receptor, CCR5. Our findings imply that GVHD should be considered in the differential diagnosis of noninfectious angiitis-like disease of the CNS in long-term survivors after allogeneic BMT. Infiltrating cells, in analogy to typical target organs of GVHD such as skin or liver, expressed CD11a and CCR5. These findings could be of etiopathological, diagnostic and therapeutic relevance.
Introduction
Allogeneic BMT and PBSCT are therapeutic options to treat hematologous malignancies and non-malignant diseases. Their application is steadily increasing, but the outcome and extensive use is limited by a wide spectrum of adverse effects. Severe neurological complications occur in up to 26% of the patients 1 and contribute to 12-26% of the overall number of deaths. 2, 3 Early complications, such as encephalopathy, cerebrovascular accidents, drug neurotoxicity and central nervous system (CNS) infections, have already been studied in detail. 4 In contrast, only limited information is available about neurological complications in the late phase after transplantation. Thus, the neurological manifestation of GVHD has been restricted to the motor endplate, skeletal muscle and peripheral nervous system, causing myasthenia gravis, polymyosistis and possibly polyneuropathy. 5 Recent clinical and experimental data suggest that GVHD also affects the CNS. We have retrospectively observed neurological deficits, cognitive impairment and magnetic resonance imaging (MRI) abnormalities in more than 50% of long-term survivors after allo-BMT in association with chronic GVHD. 6 A prospective study within the first year after transplantation confirmed a similar high rate of GVHD-related neurological abnormalities. Owing to the short follow-up period, symptoms were mild and confined to the peripheral nervous system. 3 Severe angiitis-like syndromes were reported casuistically to occur in patients with chronic GVHD, but diagnosis was based either on angiography 7 or on histological analysis, [8] [9] [10] [11] [12] [13] with a heterogenous spectrum of immunohistological methods used.
Here, we describe four long-term survivors after allogeneic BMT with biopsy-proven noninfectious angiitis-like disease of the CNS in association with chronic GVHD and their response to high-dose immunosuppressive therapy. We furthermore characterized the histological findings using immunohistochemistry (IHC) and immunofluorescence (IF), and discuss their pathophysiological and therapeutic relevance.
Patients and methods
In this study, BM recipients were included who were admitted, between 1999 and 2005, to the Neurological Department of the Klinikum Grohadern because of a progressive and heterogenous spectrum of neurological symptoms. They were three men and one woman with a mean age of 32 years, range 20-42 years. Acute GVHD was graded according to the The International Bone Marrow Transplant Registry (IBMTR) severity index; chronic GVHD grading was based on the National Institutes of Health consensus criteria.
14 Monitoring for infections included serological Ab screening and PCR tests of serum and cerebrospinal fluid (CSF), and cultures of blood, urine and sputum samples. Thus, we looked for a wide spectrum of viral (for example, HSV, VZV, Epstein-Barr (EBV), JC and BK virus, adenovirus, human herpes virus-6 and human herpes virus-7), bacterial (for example, Mycobacterium tuberculosis), fungal (for example, Aspergillus) and protozoal (for example, Toxoplasma gondii) agents. Screening for systemic vasculitis included parameters for general inflammation (erythrocyte sedimentation rate, C-reactive protein), collagen vascular disease (autoantibodies such as antinuclear Abs, antineutrophil cytoplasmic Abs, antimitochondrial Abs, double stranded DNA Abs) and coagulopathy (Lupus anticoagulant, cardiolipin Abs).
After routine neuropathological evaluation of bioptic brain tissue, we retrospectively performed IHC and IF analysis on archival formalin-fixed, paraffin-embedded brain sections (3 mm thick), as described previously. 15 The following primary Abs were used: mouse anti-human LCA (leukocyte common Ag, also stains activated microglia), cluster of differentiation (CD) 3 (pan T-cell marker), CD8 (cytotoxic T-cell marker), CD68 (marker for monocytes and microglia), Granzyme B, glial fibrillary acidic protein (all obtained from DAKO, Hamburg, Germany) and CCR5 (chemokine receptor-5, clone MC5; kindly provided by M Mack, University of Regensburg, Regensburg, Germany); rabbit anti-human CD11a (subunit of the leukocyte functionassociated Ag-1) and CCR1 (both from Abcam, Cambridge, UK). In one patient, IHC against UHCL (memory T-cell Ag) was performed on first neuropathological examination; reevaluation using LCA, CD3 and CD8 IHC could not be carried out because of lack of tissue specimen. Depending on the primary Ab, the detection cascade included biotinylated goat anti-mouse or goat anti-rabbit Igs in combination with peroxidase conjugated to streptavidin. For double IHC, the primary Abs, mouse anti-LCA and rabbit anti-CD11a, were incubated simultaneously, followed by incubation with alkaline phosphatase-conjugated goat anti-mouse and peroxidase-conjugated goat anti-rabbit Ig (all from DAKO). For double IF, first the mouse anti-LCA Ab was added, followed by incubation with biotinylated goat anti-mouse Ig, then with horse anti-goat Ig and finally with streptavidinfluoroisothiocyanate (all from Vector, Burlington, Canada); after heating in microwave oven for blockage of Ab, 16 the mouse anti-CCR5 Ab was added and detected using a rabbit anti-mouse-Cy3 fluorochrome conjugate (Jackson Immunoresearch, West Grove, PA, USA). To show the donor origin of infiltrating CD45 þ cells, in-situ-hybridization for the Y chromosome after male-to-female transplantation was performed, as previously described. 17 For detection of viral infection, IHC for EBV (LMP-Ag; DAKO) and JC virus (T-Ag, clone Pab 2003; kindly provided by R Frisque, Pennsylvania State University, Hershey, PA, USA) was performed.
Patient 1
The 35-year-old male patient received allogeneic BMT because of CML in October 1995. He developed acute skin GVHD (grade III) and later moderate chronic skin and liver GVHD. Immunosuppressive therapy with CYA and prednisolone (SDH, 7.5 mg/day p.o.) was stopped 3 years later. In June 1999-2 weeks after the termination of shortterm SDH treatment for rheumatic fever-the patient experienced several short-lasting speech arrests, intermittent acoustic phenomena (noise, music, voices) and subacute hearing loss. On admission, he presented with focal seizures of the left hand with secondary generalization. Cranial T2-weighted MRI showed hyperintense cortical/subcortical lesions in both peri-insular regions (right4left), and in the left frontal and parietal lobe without gadolinium enhancement. Hyperintense lesions on diffusion-weighted imaging and corresponding hypointense apparent diffusion coefficients indicated acute ischemia, especially in the left parietal lobe. Electroencephalography (EEG) revealed bilateral temporal slowing without epileptic discharges. Audiogram showed retrocochlear hearing loss. Laboratory tests were normal except for erythrocyte sedimentation rate (25/55 mm), elevated antinuclear Ab titers (1:480) and elevation of g-GT (292 U/l) and alkaline phosphatase (196 U/l). Repeat MRI 3 weeks after admission indicated disease progression. The patient was treated with valproic acid 500 mg thrice a day p.o. for suspected focal seizures immediately after admission. Stereotactic biopsy of a right parietal lesion revealed mild signs of microangiopathy, thus for immunosuppression, SDH (500 mg daily i.v. for 3 days, then 80 mg daily p.o.) and CY (1.5 g daily i.v. every 2-4 weeks) were started. One month later, MRI lesions had disappeared, the frequency and intensity of acoustic auras were diminished and GVHD improved to mild skin alterations. After tapering of SDH and six CY cycles in February 2000, the patient again experienced epileptic acoustic phenomena, and MRI showed a new lesion in the right parieto-insular region. Following SDH (500 mg thrice daily i.v., thereafter 70 mg daily p.o.), three courses of CY (1.5 g i.v. every 3 weeks) and long-term medication with MTX (10 mg weekly p.o.), seizures and MRI lesions resolved. The patient remained seizure-free after valproic acid was stopped and MRI remained normal except for generalized brain atrophy. The patient continues to take SDH 2.5 mg daily and MTX 5 mg weekly p.o. without serious GVHD symptoms. His neurological status remains unremarkable, 9 years after the initial CNS symptoms and 13 years after BMT.
Patient 2
A 28-year-old female patient with AML, after autologous BMT with BU and CY relapsed and received allogeneic BMT in May 2002. Acute GVHD of the skin (grade III) developed that later turned into moderate sclerodermatous chronic GVHD. She was treated with mycophenolate mofetil and SDH. The administration of mycofenolate mofetil was stopped and that of SDH was tapered below the Cushing dose in May 2004. Two months later, the patient noticed slowly progressive asthenia, impairment of visual acuity, depression and cognitive deficits. A focal epileptic seizure, deterioration of vigilance and memory were noticed another 6 months later. On the basis of abnormal EEG (left frontal spikes with generalized slowing) and cranial computer tomography, leukoencephalopathy was suspected. On admission, the patient was lethargic, disorientated, somnolent and dehydrated. Neurological examination revealed reduced visual acuity due to cortical blindness, mild spastic tetraparesis and ataxia of posture and gait. Alertness improved after rehydration, but neuropsychological testing revealed persistent severe deficits in memory, concentration, attention, visuoconstruction and abstraction. CSF examination showed a mild disturbance of the blood-brain barrier (78 mg% total protein). Oligoclonal gammopathy detected both in serum and CSF partially was specific for CSF. Brain MRI showed multiple, confluent hyperintense areas on T2-weighted images at the cerebral white matter with perivascular gadolinium enhancement (Figures 1a-c) . Magnetic resonance spectroscopy indicated loss of nerve cells, axonal damage and increased cell membrane proliferation. Visual evoked potentials revealed an increase of the P100 latency (left 151 ms, right 135 ms) typical for demyelination of the left optic nerve. EEG showed periodic lateralized bitemporal epileptiformic discharges, but a suspected nonconvulsive status epilepticus was not confirmed. The clinical status worsened and on repeat MRI, leukoencephalopathic changes progressed and internal brain atrophy was detectable. On histological analysis of bioptic parietal lobe tissue, cerebral vasculitis was diagnosed. The detection of Y-chromosome-positive lymphomononuclear cells within the vessel walls indicated that these intramural infiltrates were of donor origin (Supplementary Figure S4) . After i.v. treatment with CY (1 Â 750 mg/m 2 ) and methylprednisolone (500 mg daily for 5 days) the patient received oral immunosuppression with SDH (initially 60 mg daily, tapered to 15 mg daily) and CY (100 mg daily). Within the following weeks, cognitive deficits and visual acuity improved and spasticity resolved. EEG and visual evoked potentials normalized, leukoencephalopathy regressed and disturbance of the blood-brain barrier was not detectable any more, whereas white matter atrophy was unchanged (Figures 1d-f) . Immunosuppression with SDH and CY was sustained for the next 2 years. Now, after discontinuation of immunosuppression and 4 years after the first manifestations of neurological symptoms, the clinical status is stable and the patient was able to complete her university studies.
Patient 3
The 20-year-old male received allogeneic haploidentical T-cell-depleted BMT without induction by chemo-or radiotherapy at the age of 8 months because of SCID syndrome. Only PR was obtained and IgG subclass deficiency, requiring recurrent Ig substitution, and absence of IgA persisted. The patient suffered from chronic gastrointestinal and bronchopulmonal infections and skin At admission (a-c), MRI showed leukoencephalopathy (LE) and streaky gadolinium enhancement along the perivascular spaces. One year later, after immunosuppression with methylprednisolone and CY, follow-up MRI (d-f), revealed mild regression of LE and absence of contrast enhancement, whereas internal brain atrophy was shown (stereotactic marker ventral to the right lateral ventricle).
alterations were observed, which were atypical for GVHD. , i.v.). At discharge, the patient was more alert and temporary ocular fixation was observed. Further CY cycles were planned, but the patient died at home from acute aspiration 6 years after BMT.
Results and discussion
In the four BM recipients presented in this study, a slowly progressive subacute CNS disease occurred, which manifested with seizures, focal neurological deficits, strokes, mental changes and reduced alertness. The patients characteristics are summarized in Table 1 . Three of the (Table 2 ) revealed cerebral angiitis of small and medium-sized vessels. Lymphomononuclear infiltration was located perivascular and within the vessel wall, whereas within brain parenchyma, only scattered infiltrates were observed. The two patients with a higher degree of infiltration showed formation of perivascular lymphomonocytic cuffs, necrosis of the vessel wall, disobliteration of the vessel lumen and, in part, focal demyelination. In the other two patients, the extent of glial fibrillary acidic protein-positive astrocytosis was relatively high, probably due to a more chronic inflammatory process. LCA þ inflammatory infiltrates consisted mainly of CD3 þ and CD8 þ cytotoxic T-lymphocytes, and to a lesser degree, of CD68 þ monocytes/microglia. The expression pattern of CCR5 overlapped with CD8 immunostaining. Double IHC and IF revealed that part of the LCA þ cells also expressed CD11a or CCR5 þ (Figures 2 and 3) . CD20 þ cells were very rarely found around the vessels, and no expression of Granzyme B or CCR1 were seen. IHC for EBV and JC virus was negative in all patients. Immunosuppressive therapy in two patients resulted in normalization of clinical symptoms and a distinct improvement of MRI findings. The other patients showed an amelioration of the neurological and neuroradiological status, but died from non-neurological complications.
As there were no indications for other etiologies and owing to the clinical course, GVHD has to be considered as the cause of cerebral angiitis in our patients. Vascular neurotoxicity may arise from conditioning regimen or immunosuppression with calcineurin inhibitors such as CYA or tacrolimus. But the delay between their discontinuation and the manifestation of neurological symptoms was longer than 12 months, and not all patients had received potentially neurotoxic drugs or irradiation. Laboratory tests make any systemic autoimmune disease other than GVHD improbable. The low antinuclear Ab titer of Patient 1, often seen in BM recipients, should be regarded as unspecific, as antinuclear Ab subtyping yielded negative results. Blood ammonia levels were not elevated in the patients, and thus, hepatic encephalopathy seems improbable. In patients with liver disease, MRI lesions have been described, 18 but they were restricted to T1-weighted sequences. Negative CSF cultures, Ab response and PCR, the absence of EBV-positive and JCpositive immunohistological staining and therapeutic efficacy of high-dose immunosuppression make a solely infectious etiology rather unlikely and also do not apply Table 2 Histological and immunohistological findings of brain bioptic specimen with the diagnosis of posttransplant EBV-associated lymphoproliferative disease, a disorder that preferentially affects B cells.
Cerebral angiitis in association with chronic GVHD may involve both small and larger vessels, 13 consistent with a wide spectrum of observed MRI findings. We did not perform angiography because of its low sensitivity in the diagnosis of cerebral angiitis. 19 Only exceptionally have positive angiographic findings been described in BM recipients with cerebral angiitis. 7 Cerebral manifestation of GVHD has not been found in autopsy series, 20, 21 but mean survival of 2 months might have been too short in these studies. In contrast, cerebral infiltration has been reported in eight long-term survivors with chronic GVHD. [8] [9] [10] [11] [12] [13] The histological pattern of inflammation was consistent with our findings concerning perivascular localization of lymphomononuclear infiltrates and glial activation. Involvement of the vessel wall was present in all of our patients, whereas transmural granulomas and occurrence of giant cells, as described earlier, 10, 11 could not be detected. Meningeal vessel infiltration was also observed in one patient, but meninges were not exclusively affected as reported previously. 9 In analogy with former findings, immunohistological subtyping identified the cerebral infiltrates in our patients to be monocytes and cytotoxic T cells in the majority. As in the genetic studies of Ma et al., 11 we could show that perivascular cerebral infiltrates in the brain of Patient 2 were of donor origin using the in-situ hybridization technique. This observation is consistent with the diagnosis of cerebral GVHD, as donor lymphocytes have an essential pathophysiological role in GVHD. Furthermore, experimental data support the hypothesis that the CNS is a potential target organ during GVHD. Besides upregulation of class I and II major histocompatibility Ag on brain microglia and endothelium, 22 ,23 microglia activation and moderate brain perivascular or parenchymal mononuclear infiltration were observed in mice with GVHD. 24 In addition, we have described an upregulation of adhesion molecules on cerebral vessels in the same mouse model of GVHD. 15 Adhesion molecules and chemokines control homing of leukocytes to the CNS in inflammatory brain conditions. Here, we could further show that a high proportion of the leukocytic infiltrates in humans expressed CD11a, which is part of the adhesion receptor leukocyte function-associated Ag-1 . Leukocyte function-associated Ag-1 is thought to mediate leukocytic trafficking into the brain through interaction with intercellular adhesion molecule-1 on brain vessels during inflammatory brain conditions. 25 In addition, we observed that part of the infiltrates expressed the chemokine receptor CCR5, which is also found on leukocytes. Together with the corresponding chemokines RANTES and MIP-1, CCR5 seems to have a pathophysiological role in cellular invasion into the brain not only during MS, 26 but also into target organs of GVHD; upregulation of CCR5 on infiltrating cells has been shown during skin and liver GVHD, both in animals 27, 28 and humans. 29 Inhibiting Abs against leukocyte functionassociated Ag-1 (Efalizumab) and antagonists against CCR5 (Maraviroc) may prevent leukocyte recruitment during inflammation and have been administered to patients for the treatment of psoriasis and HIV-infection in clinical practice. Otherwise, only few studies have investigated the role of CD11a during GVHD. The immunomodulatory effect of CCR5 on GVHD either supporting or suppressing T-cell infiltration seems to be heterogenous and needs further clarification. 30 Cerebral angiitis should be discussed as a cause of late neurological complications in allogeneic BM recipients and brain biopsy considered to confirm the diagnosis of noninfectious angiitis in these patients. As diagnostic markers specific for GVHD have not been identified yet, a clear relationship between GVHD and angiitis still remains to be established and secondary vasculitides have to be excluded.
